Home / Health / Ozempic Use Quadruples in Manitoba
Ozempic Use Quadruples in Manitoba
7 Jan
Summary
- Manitoba Ozempic claims more than quadrupled in four years.
- Generic Ozempic is expected on the Canadian market this year.
- Drug's long-term effects remain unknown, experts caution.
Dispensing of the diabetes and weight-loss medication Ozempic in Manitoba has seen a significant increase, with claims quadrupling over the past four years to reach 88,367 in the 2024-25 fiscal year. This surge is occurring as generic versions of semaglutide drugs are set to enter the Canadian market, with Novo Nordisk's patent exclusivity ending on January 4th, a move unique to Canada.
While Ozempic is recognized for its efficacy in managing Type 2 diabetes and obesity, contributing to significant health improvements for patients like Hartley Macklin, concerns linger regarding its long-term health impacts. Experts like Vernon Dolinsky highlight that the full consequences of prolonged use are not yet well-understood, and potential side effects, including muscle mass loss and weight cycling, warrant careful consideration.
Health Canada currently recommends Ozempic for Type 2 diabetes patients, impacting insurance coverage and provincial pharmacare eligibility. As the drug's usage expands, the discussion around its cost, effectiveness, potential for misuse for general weight loss, and the societal pressures influencing its demand continues to evolve.
